<DOC>
	<DOCNO>NCT00861744</DOCNO>
	<brief_summary>The purpose study compare two measles , mumps rubella conjugate vaccine ( manufacture GSK Merck Company ) term immune response elicit safety six month follow-up first vaccination . Additionally , antibody persistence assess one two year administration MMR vaccine . The Protocol Posting update follow Protocol amendment 1 2 , Oct 2009 .</brief_summary>
	<brief_title>Immunogenicity GSKs ' MMR Vaccine ( 209762 ) vs. M-M-RÂ® II , When Given With Routine Vaccines 12-15 Months Age</brief_title>
	<detailed_description />
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol ( e.g . completion diary card , return followup visit ) enrol study . Male female 12 15 month age ( e.g . age 12 month day age 16 month ) time vaccination . Written inform consent obtain parent/guardian subject . Healthy subject establish medical history clinical examination enter study . Have previously receive three dos 7valent pneumococcal conjugate vaccine within first year life third dose administer least 30 day prior enrolment vaccination study vaccine . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/ administration vaccine foreseen study protocol 30 day prior vaccination 42 day vaccination , except influenza vaccine Hib vaccine . Previous vaccination measles , mumps , rubella and/or varicella . Previous vaccination hepatitis A receipt fourth dose pneumococcal conjugate vaccine . History measles , mumps , rubella , varicella/zoster hepatitis A disease . Known exposure measles , mumps , rubella and/or varicella/zoster within 30 day prior start study . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) , include human immunodeficiency virus ( HIV ) infection . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine . Hypersensitivity latex Major congenital defect serious chronic illness . History neurologic disorder seizure , include febrile seizure . Acute disease time enrolment . Administration polyclonal immunoglobulin and/or blood product six month enter study plan administration study period .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>15 Months</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Measles , Mumps , Rubella , Varicella Vaccine</keyword>
	<keyword>Children</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
	<keyword>Humans</keyword>
	<keyword>Combined Vaccine</keyword>
	<keyword>Vaccines</keyword>
</DOC>